GlassScriptPhysician profile
Darryl John Wilkens
NPI 1679678429
$1,169.33
in general payments reported to CMS, 2019-2025
20 companies · $281 in 2025
The $281 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $37.63 · 2020: $26.34 · 2021: $67.59 · 2022: $289 · 2023: $312 · 2024: $156 · 2025: $281.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $704 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $703.60 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $199.22 | 2022-2024 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $164.88 | 2024-2025 | Caplyta |
| Abbott Laboratories | $152.70 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $139.60 | 2022-2025 | |
| Glaxosmithkline, LLC. | $131.15 | 2022-2025 | Trelegy Ellipta |
| Lundbeck LLC | $64.49 | 2024 | Rexulti |
| Lilly USA, LLC | $61.39 | 2023-2025 | Jardiance |
| Exact Sciences Corporation | $41.16 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Gilead Sciences, INC. | $40.20 | 2022-2023 | |
| Teva Pharmaceuticals USA, INC. | $20.32 | 2023 | Uzedy |
| Novo Nordisk INC | $19.12 | 2019 | |
| Axsome Therapeutics, INC. | $18.68 | 2025 | Auvelity |
| Medtronic Vascular, INC. | $18.51 | 2019 | |
| Vanda Pharmaceuticals INC. | $15.76 | 2024 | Fanapt, Hetlioz |
| Xeris Pharmaceuticals, INC. | $14.93 | 2024 | Gvoke Hypopen |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $14.82 | 2022 | |
| Allergan, INC. | $13.84 | 2020 | |
| Evoke Pharma, INC. | $13.29 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $12.77 | 2023 | Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.50 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darryl Wilkens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.